BRAF and neoplasm: High T‐cell/low B‐cell gene expression signatures in pre‐treatment tumour samples from patients subsequently treated with BRAF and MEK inhibitors were associated with longer survival compared with high T‐cell/high B‐cell signatures (Brase et al., 2021).